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Abstract
Background: The receptors for adhesion of Plasmodium falciparum-infected red blood cells (RBC)
in the placenta have been identified as chondroitin-4-sulphate (C4S) proteoglycans, and the more
sulphate-rich chondroitin oligosaccharides have been reported to inhibit adhesion. Since the anti-
malarial drug chloroquine accumulates in lysosomes and alters normal lysosomal processes, the
effects of chloroquine on the lysosomal enzyme arylsulphatase B (ASB, N-acetylgalactosamine-4-
sulphatase), which removes 4-sulphate groups from chondroitin-4-sulphate, were addressed. The
underlying hypothesis derived from the recognized impairment of attachment of parasite-infected
erythrocytes in the placenta, when chondroitin-4-sulphation was increased. If chloroquine reduced
ASB activity, leading to increased chondroitin-4-sulphation, it was hypothesized that the anti-
malarial mechanism of chloroquine might derive, at least in part, from suppression of ASB.
Methods: Experimental methods involved cell culture of human placental, bronchial epithelial, and
cerebrovascular cells, and the in vitro exposure of the cells to chloroquine at increasing
concentrations and durations. Measurements of arylsulphatase B enzymatic activity, total sulphated
glycosaminoglycans (sGAG), and chondroitin-4-sulphate (C4S) were performed using in vitro assays,
following exposure to chloroquine and in untreated cell preparations. Fluorescent immunostaining
of ASB was performed to determine the effect of chloroquine on cellular ASB content and
localization. Mass spectrometry and high performance liquid chromatography were performed to
document and to quantify the changes in chondroitin disaccharides following chloroquine
exposure.
Results:  In the human placental, bronchial epithelial, and cerebrovascular cells, exposure to
increasing concentrations of chloroquine was associated with reduced ASB activity and with
increased concentrations of sGAG, largely attributable to increased C4S. The study data
demonstrated: 1) decline in ASB activity following chloroquine exposure; 2) inverse correlation
between ASB activity and C4S content; 3) increased content of chondroitin-4-sulphate
disaccharides following chloroquine exposure; and 4) decline in extent of chloroquine-induced ASB
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reduction with lower baseline ASB activity. Confocal microscopy demonstrated the presence of
ASB along the cell periphery, indicating extra-lysosomal localization.
Conclusions: The study data indicate that the therapeutic mechanism of chloroquine action may
be attributable, at least in part, to reduction of ASB activity, leading to increased chondroitin-4-
sulphation in human placental, bronchial epithelial, and cerebrovascular cells. In vivo, increased
chondroitin-4-sulphation may reduce the attachment of P. falciparum-infected erythrocytes to
human cells. Extra-lysosomal localization of ASB and reduced impact of chloroquine when baseline
ASB activity is less suggest possible mechanisms of resistance to the effects of chloroquine.
Background
The presence of the sulphated glycosaminoglycan
(sGAG), chondroitin-4-sulphate (C4S) has been demon-
strated to affect the adherence of Plasmodium falciparum-
infected erythrocytes to endothelial cells of the vascula-
ture in models of malaria [1-6]. Attachment of the P. falci-
parum-infected erythrocytes was greater when sulphation
of chondroitin-4-sulphate (C4S) was less, and increased
sulphation of C4S reduced attachment of infected eryth-
rocytes. Also, severity of malarial infection has been asso-
ciated with the extent of sulphation of chondroitin-4-
sulphate of the intervillous cells of the placenta in models
of maternal-fetal transmission of malaria [7-12]. Since the
accumulation of infected erythrocytes induces the capil-
lary damage and organ dysfunction pathognomonic of
malaria, consideration of the possible role of the enzyme
arylsulphatase B (ASB; N-acetylgalactosamine-4-sul-
phatase), which hydrolyzes the 4-sulphate group of C4S,
was of interest.
In humans, the enzyme ASB has been regarded as solely a
lysosomal enzyme, since inborn deficiency of ASB causes
the lysosomal storage disease Mucopolysaccharidosis VI
(MPS VI), also known as Maroteaux-Lamy syndrome. In
MPS VI, the accumulation of sulphated glycosaminogly-
cans, including C4S and dermatan sulphate, produces
severe organ dysfunction and premature death. Signifi-
cant effects of the enzyme ASB on the content of C4S in
human colonic, bronchial, and mammary epithelial cells
in tissue culture [13-16] were reported recently. These
reports demonstrated extra-lysosomal localization of ASB
in human colonic and bronchial epithelial cell, as well as
other significant biological effects of ASB, affecting cell
signaling, cell migration, and inflammation [13-17].
Since ASB activity affects the sulphation of C4S and sul-
phation of C4S affects the attachment of P. falciparum-
infected red blood cells, modifications of ASB activity
might influence malarial infectivity. If the lysosomotropic
anti-malarial drug chloroquine could affect the activity of
the enzyme ASB, this might influence disease activity and
might explain, at least to some extent, the anti-malarial
effect of chloroquine. In this report, evidence of the effect
of chloroquine on ASB activity and C4S content in human
placental, bronchial epithelial, and cerebrovascular cells
in tissue culture is presented.
Methods
Cells and cell culture
Human placental fibroblastic (ATCC; Manassas, VA,
USA), bronchial epithelial (C38 and IB3-1; ATCC), pri-
mary bronchial epithelial (BEC; Clonetics® NHBE, Lonza,
Walkersville, MD, USA), and primary cerebrovascular
cells [CVC; ScienCellTM HBMEC (human brain microvas-
cular endothelial cells), Carlsbad, CA] were obtained and
grown according to recommendations and as previously
reported [13-15]. IB3-1 and C38 cells were grown in 75 ml
flasks coated with human fibronectin (10 μg/ml, Sigma-
Aldrich, St. Louis, MO), vitrogen (30 μg/ml, Cohesion),
and bovine serum albumin (10 μg/ml), using LHC-8
medium without phenol red (Invitrogen, Carlsbad, CA),
containing 0.5 ng/ml recombinant epidermal growth fac-
tor, 6 mM glutamine, 0.005 mg/ml insulin, 500 ng/ml
hydrocortisone, 0.035 mg/ml bovine pituitary extract,
and 50 μg/ml gentamicin. Primary bronchial epithelial
cells (BEC) were grown in BEGM® (Clonetics). Cerebrov-
ascular cells were grown in ECM (ScienCell), and placen-
tal cells were grown in DMEM with 10% FBS. All cells
were grown in a 5% CO2 environment at 37°C and 95%
humidity. Cells reached 80% confluence in about one
week and were harvested by scraping, or by recommended
EDTA-trypsin subculture reagent. Cell preparations were
processed for measurements of ASB activity, ASB protein
and mRNA expression, cell protein, sGAG, and C4S in
control samples and following treatment with chloro-
quine (Sigma Chemical Company, St. Louis, MO) for 24
hours at a concentration of 50 nM, unless stated other-
wise. CVC cells stained positively for CD31 using a stand-
ard protocol [Santa Cruz Biotechnology (SCBT), Santa
Cruz, CA].
Measurement of ASB activity
ASB measurements were by a fluorometric assay using the
synthetic substrate 4-methylumbilliferyl sulphate (4-
MUS), following a standard protocol [13-17]. Protein
content of the cell homogenate was measured using BCA™
Protein Assay Kit (Pierce), and ASB activity was expressed
as nmol/mg cell protein/hr. ASB protein in the controlMalaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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and chloroquine-treated cells was measured by a FACE-
ELISA (fast-activated cell-based ELISA; Active Motif, CA).
Placental cells were grown in a 96-well plate and treated
with chloroquine 50 nM × 24 hours). Treated and control
cells were washed and fixed with 4% formaldehyde in
PBS. After 20 minutes, formaldehyde was aspirated, cells
were washed with PBS, and treated with quenching buffer,
to suppress endogenous peroxidase activity. Cells were
treated with blocking buffer and incubated overnight at
4°C with polyclonal rabbit antibody to ASB (1:50; Open
Biosystems, Huntsville, AL). Binding of primary antibod-
ies to cells was detected by secondary goat anti-rabbit IgG-
HRP, and bound HRP activity was developed by hydrogen
peroxide/TMB substrate. The reaction was stopped by 2N
sulfuric acid, and the optical density was measured in an
ELISA plate reader (FLUOstar, BMG Labtech, Cary, NC) at
450 nm. After the reading, cells were washed thoroughly
and incubated in crystal violet solution for 30 minutes,
followed by 1% SDS (sodium dodecyl sulfate) solution
for one hour. Colour was proportionate to the cell
number which was measured by optical density using the
ELISA plate reader at 592 nm. This reading was used to
normalize the first reading (per equal number of cells),
and the result was expressed as % of control for the ASB
protein.
Measurement of sulphated glycosaminoglycans
Total sulphated glycosaminoglycan (sGAG) content,
including chondroitin-4-sulphate (C4S), chondroitin-6-
sulphate (C6S), keratan sulphate, dermatan sulphate,
heparan sulphate, and heparin, was measured in cell
lysates by sulphated GAG assay (Blyscan™, Biocolor Ltd,
Newtownabbey, Northern Ireland), using labeled 1,9-
dimethylmethylene blue, as previously reported [14-16].
Hyaluronan and degraded disaccharide fragments were
not measured by this assay. The reaction was performed in
the presence of excess unbound dye. The cationic dye and
GAG at acid pH produced an insoluble dye-GAG complex,
and the GAG content was determined by the amount of
dye that was recovered from the test sample following
exposure to Blyscan Dissociation Reagent. Absorbance
maximum of 1,9-dimethylmethylene blue is 656 nm.
Concentration is expressed as μg/mg protein of cell lysate.
Dye-GAG complex is proportional (1:1) to the sulphate
content for C4S.
Immunoprecipitation of cell lysates by chondroitin-4-
sulphate
Cell lysates were prepared from chloroquine-treated and
control cells. Chondroitin-4-sulphate (C4S; 4D1) anti-
body to native C4S was procured (SCBT). No prior enzy-
matic digestion of the cell samples by chondroitinase ABC
was performed. Antibody was added to the cell lysates in
tubes (C4S antibody at a concentration of 1 μg/mg pro-
tein; CS to a final dilution of 1:50), and the tubes were
rotated overnight in a shaker at 4°C, as previously
reported [14]. Next, 100 μl of pre-washed Protein L-Agar-
ose (Santa Cruz) was added to each tube, tubes were incu-
bated overnight at 4°C, and the Protein L-Agarose treated
beads were washed three times with PBS containing Pro-
tease Inhibitor Cocktail. The precipitate was eluted with
dye-free elution buffer and subjected to sulphated GAG
assay.
ASB Knockdown by siRNA
Small interfering RNA (siRNA) to knockdown ASB
(NM_000046) was obtained commercially (Qiagen,
Valencia, CA) and tested for effective knockdown by West-
ern blot and by ASB activity assay. siRNA for ASB (150 ng;
0.6 μl) in 100 μl serum-free culture medium and 12 μl of
HiPerfect Transfection Reagent (Qiagen) were combined,
as previously described [14-16]. For ASB silencing, the
siRNA sequences were:
Sense: 5'-GGGUAUGGUCUCUAGGCAtt-3'
Antisense: 5'-UUGCCUAGAGACCAUACCCtt-3'
For the negative control, the siRNA sequences were:
Sense: 5'-UUCUCCGAACGUGUCACGUtt-3'
Antisense: 5'-ACGUGACACGUUCGGAGAAtt-3'
Confocal microscopy
For confocal microscopy, the BEC or CVC were grown in
four-chamber tissue culture slides for 24 hours, as previ-
ously described [16]. Half of the wells were treated with
chloroquine 50 nM for 24 hours; cells were then fixed in
95% ethanol for 30 min and refrigerated. Slides were
washed once in 1× PBS containing 1 mM calcium chloride
(pH 7.4) and permeabilized with 0.08% saponin. Prepa-
rations were washed with PBS, blocked with 5% normal
goat serum, and incubated overnight with ASB polyclonal
antibody (Open Biosystems, ThermoFisher Scientific,
Hunstville, AL) at 4°C. Specificity of the ASB antibody
was determined by inhibition of positive staining with the
peptide that was the epitope for generation of the anti-
body. Slides were washed and stained with goat-anti-rab-
bit Alexa Fluor® IgG 568 (1:100, Invitrogen) and with
Alexa Fluor® Phalloidin 488 (1:60, Invitrogen) to stain
actin in the CVC cell preparations. Slides were washed
thoroughly, and stained cells were observed with a Zeiss
LSM 510 laser scanning confocal microscope (excitation
488 nm and 534 nm from an Ar/Kr laser. Green (F-actin)
and red (ASB) fluorescence were detected through LP505
and 585 filters. The fluorochromes were scanned sequen-
tially, and the collected images were exported by Zeiss
LSM Image Browser software as TIFF files for analysis and
reproduction.Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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QPCR for ASB mRNA expression
C38 and IB3-1 lung epithelial cells were grown in 12-well
tissue culture plates and treated with chloroquine 50 μM
for 24 hours. At the end of the treatment, total RNA was
isolated by RNeasy mini kit (Qiagen) from three control
and three treated cell preparations. Three aliquots of equal
amounts of RNA from each control or chloroquine-
treated cell preparation were reverse transcribed and then
amplified for 40 cycles, using Brilliant SYBR Green QRT-
PCR MasterMix kit (Stratagene) and Mx3000P QRT-PCR
system (Stratagene). ASB mRNA expression in control and
treated cells was determined by amplification with the fol-
lowing primers for ASB (NCBI NM_000046), that were
designed using Primer 3 software:
ASB forward: 5'AGACTTTGGCAGGGGGTAAT-3'
ASB reverse: 5'CAGCCAGTCAGAGATGTGGA-3'
Human β-actin was used an internal control. Fold changes
in ASB mRNA expression due to chloroquine treatment
were determined from the differences between the cycle
thresholds using the following formulae and CT values
that were the mean of nine determinations:
Fold change = 2Δ3 with Δ3 = Δ1 - Δ2, where Δ1 = CT con-
trol ASB - CT control actin and Δ2 = CT treated ASB - CT
treated actin
Isolation and purification of GAGs from cells
Cell samples were freeze dried and defatted by washing
the samples with chloroform/methanol mixture of (2:1,
1:1, 1:2 (v/v)) each left overnight. The defatted samples
(in 1 ml water) were individually subjected to proteolysis
at 55°C with 10% of actinase E (20 mg/ml; Kaken Bio-
chemicals, Tokyo, Japan) for 18 h. After proteolysis, dry
urea and dry CHAPS were added to each sample [2 wt %
(%, w/v) in CHAPS and 8 M in urea]. Particulates were
removed from the resulting solutions by passing each
through a syringe filter containing a 0.22 μm membrane.
A Vivapure MINI Q H spin column [Viva Science (Edge-
wood, NJ)] was prepared by equilibrating with 0.5 ml of
8 M urea containing 2% CHAPS (pH 8.3). The clarified,
filtered samples were loaded onto and run through the
Vivapure MINI QH spin columns under centrifugal force
(1000 × g). The columns were first washed with 0.5 ml of
8 M urea containing 2% CHAPS at pH 8.3. The columns
were then washed five times with 0.5 ml of 200 mM NaCl.
GAGs were released from the spin column by washing 1
time with 0.5 ml of 16% NaCl. Methanol (2 ml) was
added to afford an 80 vol% (%, v/v) solution and the mix-
ture was equilibrated at 4°C for 18 h. The resulting precip-
itate was recovered by centrifugation (2500 × g) for 15
min. The precipitate was recovered by dissolving in 1.0 ml
of water. GAG solution was desalted using spin mem-
brane (YM-3, 3000 MWCO, Millipore, Bedford, MA).
GAGs were recovered and dissolved in 0.5 ml of water,
and the recovered GAGs were stored frozen for further
analysis.
Enzymatic depolymerization of GAGs
GAG samples were incubated with chondroitinase ABC
(10 milliunits; Seikagaku, Tokyo, Japan) and chondroiti-
nase ACII (5 milli-units Seikagaku Corporation, Tokyo,
Japan) at 37°C for 10 h. The enzymatic products were
recovered by the centrifugal filtration (YM-3, Millipore).
CS/DS disaccharides passed through the filter, were
freeze-dried and ready for LC-MS analysis.
Disaccharide composition analysis using liquid 
chromatography-mass spectrometry (LC-MS)
Unsaturated disaccharide standards of CS/DS (ΔDi-0S
ΔUA-GalNAc,  ΔDi-4S  ΔUA-GalNAc4S,  ΔDi-6S  ΔUA-
GalNAc6S, ΔDi-UA2S ΔUA2S-GalNAc, ΔDi-diSB ΔUA2S-
GalNAc4S, ΔDi-diSD ΔUA2S-GalNAc6S, ΔDi-diSE ΔUA-
GalNAc4S6S,  ΔDi-triS  ΔUA2S-GalNAc4S6S) were
obtained (Seikagaku).
The LC-MS analysis was performed on a LC-MS system
(Agilent, LC/MSD trap MS). Solutions A and B for HPLC
were 0% and 75% acetonitrile, respectively, containing
the same concentration of 15 mM Hexylamine (HXA) and
100 mM 1,1,1,3,3,3,-hexafluoro 2-propanol (HFIP). The
flow rate was 100 μl/min. The separation was performed
on an ACQUITY UPLCTM BEH C18 column (Waters, 2.1 ×
150 mm, 1.7 μm) at 45°C using solution A for 10 min,
followed by a linear gradient from 10 to 40 min of 0% to
50% solution B. The column effluent entered the source
of the ESI-MS for continuous detection by MS. The elec-
trospray interface was set in positive ionization mode
with the skimmer potential 40.0 V, capillary exit 40.0 V
and a source of temperature of 350°C to obtain maxi-
mum abundance of the ions in a full scan spectra (150-
1500 Da, 10 full scans/s). Nitrogen was used as a drying
(8 liters/min) and nebulizing gas (40 p.s.i.). The data were
collected by UV and mass, respectively. Extracted ion
chromatography (EIC) was processed using Bruck soft-
ware.
Statistical analysis
Statistical significance of the data was analyzed using
Instat software. Unless stated otherwise, one-way ANOVA
with Tukey-Kramer post-test was performed with p < 0.05
considered significant. At least three independent experi-
ments were performed for each analysis, and technical
replicates of each sample were performed. In the figures,
*** represents p < 0.001, ** p < 0.01, and * p < 0.05.Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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Results
Chloroquine reduces ASB activity
ASB activity post exposure to chloroquine (50 nM × 24
hours) was measured in the human placental, bronchial
epithelial, and CVC cells. In the placental cells, ASB activ-
ity post-chloroquine exposure declined by ~50%, from a
baseline of 83.5 ± 9.8 nmol/mg/h to 41.6 ± 3.6 nmol/mg/
h (Figure 1A). In the C38 and IB3-1 cells, progressive
decline in ASB activity followed exposure to increasing
concentrations of chloroquine (Figure 1B; p < 0.0001 for
linear trend). When ASB was silenced by siRNA in the
CVC cells, the decline in ASB activity was greater than the
decline following chloroquine, but both were significant
(Figure 1C; p < 0.001, 1-way ANOVA with Tukey-Kramer
post-test). The decline in ASB activity following chloro-
quine was proportional to the baseline activity, with great-
est decline in the CVC that had the highest initial level
(Figure 1D).
Chloroquine increases total sulphated glycosaminoglycans 
(sGAG) and chondroitin-4-sulphate (C4S)
Marked increase in sGAG followed exposure to chloro-
quine in the placental, IB3-1, C38, and CVC cells (Figures
2A, B, C), consistent with reduced ASB activity leading to
accumulation of sGAG. When cell lysates were immuno-
precipitated with the C4S antibody and the resulting
sGAG measured by the Blyscan assay (Figures 3A, B, C), it
was apparent that the increase in sGAG was largely attrib-
utable to increase in C4S, and was consistent with a spe-
cific effect on reduction of ASB activity by chloroquine.
The increases in sGAG and C4S with increasing concentra-
tions of chloroquine showed a linear trend in the C38 and
IB3-1 cells (Figure 3B; p < 0.0001). In the CVC, increases
in sGAGs and C4S following chloroquine were somewhat
less than following ASB silencing, but both were signifi-
cant (Figure 3C; p < 0.001, 1-way ANOVA with Tukey-
Kramer post-test). ASB activity was inversely correlated
with C4S content in the four cell lines tested (Figure 3D).
Disaccharide composition of CVC, IB3-1 and C38 cells
Disaccharide composition of treated and control CVC is
listed in Table 1. Because of partial peak overlap, quanti-
fication relied on MS using a method previously demon-
strated for heparan sulfate disaccharide analysis [18].
Figure 4 (also see Additional File 1) is extracted ion chro-
matography (EIC) of CS/DS disaccharide analysis of CVC
cells. The percentage of C4S increased significantly in the
CVC.
The chondroitin sulphate content in the C38 and IB3-1
cells that were grown to confluency in a T75 flask was cal-
culated by a quantitative method for HPLC. The peak
areas of CS disaccharide standards in UV chromatography
are functions of their amounts. Based on the linear rela-
tion between the UV peak areas, the amount of disaccha-
rides in C38 and IB3-1 cells was calculated. In the C38
cells, the CS content was 70 μg and increased to 310 μg
following chloroquine. In the IB3-1 cells, the chondroitin
sulfate increased from 330 μg to 650 μg following chloro-
quine. In the C38 and IB3-1 cells, the percentage of C4S
disaccharides varied less following chloroquine than in
the CVC.
Confocal imaging of ASB in CVC and bronchial epithelial 
cells
Confocal images of ASB were obtained following fluores-
cent immunostaining, in which ASB appears red and β-
actin appears green (Figure 5A, B). The presence of ASB
was demonstrated along the cell periphery, consistent
with membrane localization. Nuclear and cytoplasmic
localization were also evident. The membrane localiza-
tion was unexpected, since ASB had been regarded as
solely a lysosomal enzyme. In the primary bronchial epi-
thelial cells (BEC), fluorescent immunostaining for ASB
was markedly reduced following exposure to chloroquine
(Figure 5C) vs. untreated control (Figure 5D), and was evi-
dent along the cell periphery.
ASB activity, ASB protein content, mRNA expression, and 
total sGAG
The ASB protein content in the placental cells was meas-
ured by a Fast Activated Cell-based ELISA (FACE) and
compared with the ASB activity after exposure to chloro-
quine 50 nM for 24 hours. ASB activity declined from 83.5
± 9.8 to 41.6 ± 3.6 nmol/mg protein/hr (to 49.8% of base-
line), and ASB protein content declined to 47.6 ± 5.2% of
the baseline, indicating the close correspondence between
the activity measurement and the FACE assay.
Placental cells were treated with chloroquine 50 nM × 24
hours and fresh media added at 24 and 48 hours. Spent
media were collected at 24, 48, and 72 hours, and ASB
activity (Figure 6A) and total sGAG were measured (Figure
6B). ASB activity nadir was at 24 hours, with return to
baseline by 72 hours. Inversely, the sGAG content peaked
at 24 hours and returned to baseline by 72 hours. These
findings indicate that the effects of chloroquine exposure
on ASB activity and sGAG content are prolonged beyond
the time of direct exposure, but have dissipated by 72
hours.
Following chloroquine treatment in the C38 and IB3-1
cells, the mRNA expression of ASB declined significantly,
in contrast to β-actin expression (Figure 6C). ASB cycle
threshold (CT) in untreated C38 cells was 29.7 ± 0.2 com-
pared to CT of 32.4 ± 0.4 in the chloroquine-treated cells,
with β-actin values of 30.3 ± 0.9 and 29.4 ± 0.2. Similarly,
in the IB3-1 cells, CT for ASB in control cells was 31.0 ±
0.2 and increased to 33.8 ± 1.3 following chloroquine
exposure, with β-actin values of 29.5 ± 0.3 and 30.1 ± 0.4.Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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ASB activity declines following exposure to chloroquine (CQ) Figure 1
ASB activity declines following exposure to chloroquine (CQ). ASB activity declined in the placental fibroblasts follow-
ing chloroquine exposure (Panel A; p = 0.02, unpaired t-test, two-tailed). ASB activity was significantly higher in the C38 than 
in the IB3-1 cells. Following exposure to increasing concentrations of chloroquine, the ASB activity declined linearly in both cell 
lines (Panel B; p < 0.0001, 1-way ANOVA for linear trend; r2 = 0.89 for C38 and r2 = 0.86 for IB3-1). In the CVC, chloroquine 
exposure produced significant reduction in ASB activity (Panel C; p < 0.001, 1-way ANOVA with Tukey-Kramer post-test). 
Following ASB silencing by siRNA, the ASB activity was reduced more than by chloroquine. The extent of reduction in ASB 
activity is less when the baseline ASB activity is less, as demonstrated by the direct correlation between the change in ASB 
activity and the baseline ASB activity (Panel D; r = 0.91). [con si = control siRNA; ASB si = ASB siRNA; CVC = cerebrovascu-
lar cells; PC = placental cells; ASB = arylsulphatase B].Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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Increased total sulphated glycosaminoglycan (sGAG) content following chloroquine exposure Figure 2
Increased total sulphated glycosaminoglycan (sGAG) content following chloroquine exposure. In the placental 
cells, the sGAG content increased significantly following chloroquine (50 nM × 24 hours) (Panel A; p = 0.02, unpaired t-test, 
two-tailed). Similarly, the sGAG content increased linearly in response to exposure to increasing concentrations of chloro-
quine (Panel B; p < 0.0001, 1-way ANOVA for linear trend; r2 = 0.92 for C38 cells and r2 = 0.96 for IB3-1 cells). For the CVC, 
the increase in sGAG was significant following chloroquine (50 nM × 24 hours) and ASB siRNA (× 24 hours) (Panel C; p < 
0.001, 1-way ANOVA with Tukey-Kramer post-test). [con si = control siRNA; ASB si = ASB siRNA; CVC = cerebrovascular 
cells; PC = placental cells; ASB = arylsulphatase B].Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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Increased chondroitin-4-sulphate (C4S) content following chloroquine exposure Figure 3
Increased chondroitin-4-sulphate (C4S) content following chloroquine exposure. The concentration of C4S 
increased significantly following exposure to increasing concentrations of chloroquine in the placental cells for 24 hours (Panel 
A; p = 0.002, unpaired t-test, two-tailed) and in the C38 and IB3-1 cells for 24 hours (Panel B; p < 0.0001, 1-way ANOVA for 
linear trend; r2 = 0.96 for C38 cells and r2 = 0.96 for IB3-1 cells). For the CVC cells, the increase in C4S was significant follow-
ing chloroquine (50 nM × 24 hours) and ASB siRNA (× 24 hours) (Panel C; p < 0.001, 1-way ANOVA with Tukey-Kramer 
post-test). The decline in ASB activity was inversely correlated with the increase in C4S content (Panel D; r = 0.94). [con si = 
control siRNA; ASB si = ASB siRNA; CVC = cerebrovascular cells; PC = placental cells].Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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Extracted ion chromatography (EIC) representation of disaccharide composition in cerebrovascular cells before and after  exposure to chloroquine Figure 4
Extracted ion chromatography (EIC) representation of disaccharide composition in cerebrovascular cells 
before and after exposure to chloroquine. The HPLC system used resolves the eight CS disaccharide standards (Panel 
A). Despite the variability of retention time due to variable quantities of residual buffer salts, peak identity was easily confirmed 
by co-injection with single known CS disaccharide standards as well as from their MS (see Additional File 1) or by MS/MS spec-
tra. CVC controls (Panels B, D, and F) and CVC after chloroquine treatment (Panels C, E, and G) are shown. The chlo-
roquine-treated CVC demonstrate marked increase in the peak for C4S disaccharide (ΔDi-4S) following chloroquine exposure 
(Panels E and G vs. Panel F). Additional peaks observed early (3-8 min) in the chromatograms B, D, and F and well sepa-
rated from the sulpho-group containing CS standards are residual contaminants from cells and media and do not interfere with 
the analysis.Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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These results indicate a 12-fold decrease in ASB mRNA
expression in the C38 cells and a 5-fold decrease in the
IB3-1 cells following chloroquine exposure.
Discussion
The study findings indicate that exposure to chloroquine
reduced the ASB activity and expression and, correspond-
ingly, increased the content of chondroitin-4-sulphate, as
well as total sGAGs, in human placental, bronchial, and
cerebrovascular cells. C4S has been identified as the cell
surface molecule associated with adherence of infected
erythrocytes to Saimiri brain and human lung endothelial
cells, as well as placental cells [2]. Since low-sulphated
chondroitin sulphate has been implicated in the increased
adherence of P. falciparum-infected red blood cells in the
human placenta [7-12], the in vitro findings in this report
may be relevant to the mechanism of clinical infection,
particularly if placental infections are attributable to the
expression of novel variant surface antigens that bind
preferentially to C4S [19]. Reduced ASB activity and the
associated increase in C4S sulphation in human vascular
or bronchial cells post-chloroquine may hinder the
attachment of parasite-infected erythrocytes in vivo.
The low-sulphated chondroitin sulphate proteoglycan
receptors of placenta are found predominantly in the
intervillous space, and parasite-infected red blood cells
sequester in the human placenta through attachment to
C4S. The major attachment to C4S is reported to be by the
Plasmodium falciparum erythrocyte membrane protein 1
(PfEMP1), encoded by the var2csa gene [20].
Chloroquine has been found to accumulate in lysosomes,
and by effects on lysosomal pH, its exit from the lysosome
is prevented [21,22]. Since ASB is also found in the lyso-
some, chloroquine, by effects on lysosomal pH, may
reduce the lysosomal ASB activity in vivo, since ASB func-
tions optimally at low pH. The study finding that chloro-
quine exposure reduced the mRNA expression of ASB, as
well as the ASB protein and activity in the in vitro assay,
indicates that chloroquine directly affects mRNA content.
Study data (not shown) demonstrated that activity of the
lysosomal enzyme galactose-6-sulphatase (GALNS) also
declined post-chloroquine exposure in the CVC and pla-
cental cells, although the decline was not as much as that
found in ASB activity.
Chloroquine has been used for treatment of malarial
infections for many decades. The mechanism of action of
chloroquine has been attributed to various effects, includ-
ing entrapment in the parasite's food vacuole, inhibition
of haem polymerase with accumulation of the toxic
Fe(II)-protoporphyrin IX-chloroquine complex that dis-
rupts membrane function and leads to parasite autodiges-
tion, or interference with nucleic acid biosynthesis by
intercalation with parasitic DNA [21-23]. The current
study findings neither refute nor support these mecha-
nisms, but suggest an additional biochemical mechanism
to explain the effect of chloroquine.
The study data suggest that development of resistance to
chloroquine may be, at least in part, attributable to the
presence of extra-lysosomal ASB, which would be unaf-
fected by chloroquine that is accumulated and seques-
tered in the lysosomes. Also, since the decline in ASB
activity was less when the baseline ASB activity was less,
the effectiveness of chloroquine might be expected to
diminish as ASB activity declined.
Further attention to the effects of ASB on sulphation of
C4S may facilitate development of innovative anti-malar-
ial therapies. Improved understanding of the mechanism
Table 1: CS/DS disaccharide composition of cerebrovascular cells*
Composition (%) ΔDi-0S ΔDi-UA2S ΔDi-6S ΔDi-4S ΔDi-diSD ΔDi-diS ΔDi-diSE ΔDi-triS
CVC-cont-1 n.d. 8.5 84.3 7.2 n.d. n.d. n.d. n.d.
CVC-1 n.d. 10.3 43.9 45.2 0.22 0.08 0.3 n.d.
CVC-cont-2 n.d. 7 90 3 n.d. n.d. n.d. n.d.
CVC-2 n.d. 17.3 16.2 66 0.09 0.02 0.39 n.d.
CVC-cont-3 n.d. 8.1 84.9 7 n.d. n.d. n.d. n.d.
CVC-3 n.d. 24.1 22.9 52.2 0.12 0.03 0.65 n.d.
*CS = chondroitin sulphate; DS = dermatan sulphate; CVC = cerebrovascular cells; cont = control; CVC-1, CVC-2, CVC-3 = chloroquine-treated; 
n.d. = not detected
DDi-0S: 2-acetamido-2-deoxy-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
DDi-4S: 2-acetamido-2-deoxy-4-O-sulphosulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
DDi-6S: 2-acetamido-2-deoxy-6-O-sulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
DDi-UA2S: 2-acetamido-2-deoxy-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
DDi-diSB: 2-acetamido-2-deoxy-4-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronicacid)-D-galactose
DDi-diSD: 2-acetamido-2-deoxy-6-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronicacid)-D-galactose
DDi-diSE: 2-acetamido-2-deoxy-4,6-di-O-sulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
DDi-triS: 2-acetamido-2-deoxy-4,6-di-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose acid)-D-galactoseMalaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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of action of chloroquine might provide new insight into
mechanisms of resistance, leading to improved therapeu-
tic approaches to what remains one of the most prevalent
and deadly infectious diseases.
Conclusions
Study data demonstrate that exposure of human placen-
tal, bronchial, and cerebrovascular cells in tissue culture
to chloroquine leads to reduced mRNA and protein
expression and activity of the enzyme arylsulphatase B,
and to increased cellular content of chondroitin-4-sul-
phate, as well as total sulphated glycosaminoglycans.
Since the degree of sulphation of chondroitin-4-sulphate
has been associated with the attachment of P. falciparum-
infected erythrocytes to the intervillous cells of the pla-
centa, chloroquine-induced decline in ASB activity, with
the accompanying increase in chondroitin-4-sulphation,
may produce its anti-malarial effect. Extra-lysosomal ASB
and the decline in further reduction of ASB activity at
lower activity levels may contribute to development of
resistance to chloroquine.
Abbreviations
ASB: arylsulphatase B; BEC: bronchial epithelial cell; C4S:
chondroitin-4-sulphate; CVC: cerebrovascular cell; CQ:
chloroquine; CT: cycle threshold; EIC: extracted ion chro-
matography GAG: glycosaminoglycan; LC-MS: liquid
chromatography-mass spectrometry; MPS: mucopolysac-
Confocal microscopy demonstrates cell surface localization of ASB Figure 5
Confocal microscopy demonstrates cell surface localization of ASB. Confocal microscopy demonstrates the pres-
ence of peripheral localization of ASB in the CVC, as well as cytoplasmic and nuclear localization. ASB is stained red, and β-
actin is stained green (Panels A, B). In primary bronchial epithelial cells, exposure to chloroquine (50 nM × 24 hours) pro-
duced marked reduction in ASB fluorescent immunostaining (Panel C), compared to untreated control (Panel D). [CVC = 
cerebrovascular cells; ASB = arylsulphatase B; BEC = bronchial epithelial cells].Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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Relationship between ASB activity and total sGAG following chloroquine exposure over 72 hours Figure 6
Relationship between ASB activity and total sGAG following chloroquine exposure over 72 hours. Chloroquine 
(50 nM) was administered for 24 hours, the spent media removed, and fresh media without chloroquine was supplied at 24 and 
48 hours. ASB activity (Panel A) and total sGAG (Panel B) were measured in spent media at 24, 48, and 72 hours, as shown. 
ASB activity rose from the nadir at 24 hours and returned to baseline by 72 hours (p < 0.001 at 24 and 48 hours; 1-way 
ANOVA with Tukey-Kramer post-test). Inversely, the sGAG content peaked at 24 hours and returned to baseline by 72 hours 
(p < 0.001 at 24 hours, p < 0.01 at 48 hours; 1-way ANOVA with Tukey-Kramer post-test). QPCR demonstrated less baseline 
mRNA expression of ASB in the IB3-1 cells than in the C38 cells (Panel C), and declines in both cell lines following exposure 
to chloroquine (50 μM × 24 hours). Cycle threshold of ASB was calculated in comparison to cycle threshold of β-actin, which 
varied only from 29.36 to 30.27.Malaria Journal 2009, 8:303 http://www.malariajournal.com/content/8/1/303
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charidosis; QPCR: quantitative polymerase chain reac-
tion; sGAG: sulphated glycosaminoglycan; RBC: red
blood cell; PfEMB1: Plasmodium falciparum erythrocyte
membrane protein-1.
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Detailed mass spectrometry data of cerebrovascular cell disaccharides. 
The file contains detailed analysis of the cerebrovascular cell disaccharides 
that were present following isolation and purification of the cellular 
sGAG, followed by their enzymatic depolymerization, and separation and 
detection by LC-MS, as detailed in the Methods. Figure 4A presents peaks 
of the disaccharide standards, including ΔDi-0S, ΔDi-UA2S, ΔDi-6S, 
ΔDi-4S, ΔDi-diSD, ΔDi-diSB, ΔDi-diSE, and ΔDi-triS. Figures 4B-4G 
present mass spectra for ΔDi-0S, ΔDi-UA2S, and ΔDi-6S, in the control 
(4B,4F) or chloroquine-treated (4C,4E,4G) cerebrovascular cells, with 
demonstrable changes in amplitude of the peaks for the disaccharides of 
major interest in this report.
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